Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bushen Ningxin Decoction with or without Femoston for premature ovarian insufficiency with circadian rhythm disorder
ChiCTR2100055043Phase 4Recruiting
- Sponsor
- Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Jiangsu Provincial Hospital of Traditional Chinese Medicine
- Start
- Jan 2022
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of estradiol and Bushen Ningxin Decoction in ovarian hypofunction (POI) and circadian rhythm sleep disorder (CRSD) (3 arms), sponsored by Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Jiangsu Provincial Hospital of Traditional Chinese Medicine. Primary endpoints: serum follicle-stimulating hormone level, ovulation rate and 3 more. Started Jan 2022; status: recruiting.
02
Drugs
estradiolBushen Ningxin Decoction
03
Conditions
ovarian hypofunction (POI)circadian rhythm sleep disorder (CRSD)
Beyond the preview
Go deeper on ChiCTR2100055043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100055043.